Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases

Ji, Eunhye; Lee, Sahmin

doi:10.3390/ijms22115770

Cited by 42 publications

(22 citation statements)

References 140 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, for the detection of antibodies for other purposes (e.g. to monitor immunotherapy), the concentration level of the target antibody can be much higher (high nM low uM range) (Robert et al, 2001;Ji and Lee, 2021;Chames et al, 2009). Thus, the C HalfMax values we achieved here (Figure 4B) show sensitive concentration ranges relevant for diagnostic applications.…”

Section: Discussionmentioning

confidence: 85%

Single antibody detection in a DNA origami nanoantenna

et al. 2021

View full text Add to dashboard Cite

DNA nanotechnology offers new biosensing approaches by templating different sensor and transducer components. Here, we combine DNA origami nanoantennas with label-free antibody detection by incorporating a nanoswitch in the plasmonic hotspot of the nanoantenna. The nanoswitch contains two antigens that are displaced by antibody binding, thereby eliciting a fluorescent signal. Singleantibody detection is demonstrated with a DNA origami integrated anti-digoxigenin antibody nanoswitch. In combination with the nanoantenna, the signal generated by the antibody is additionally amplified. This allows the detection of single antibodies on a portable smartphone microscope. Overall, fluorescence-enhanced antibody detection in DNA origami nanoantennas shows that fluorescence-enhanced biosensing can be expanded beyond the scope of the nucleic acids realm.

show abstract

Section: Discussionmentioning

confidence: 85%

Single antibody detection in a DNA origami nanoantenna

et al. 2021

View full text Add to dashboard Cite

show abstract

“…An expert committee published the National Cholesterol Education Program in United States, emphasizing that low density lipoprotein (LDL) should be the primary target of cholesterol-lowering therapy in atherosclerosis ( Tavares et al, 2021 ). In particular, clinical trials have demonstrated that lowering LDL levels can reduce the risk of atherosclerosis ( Ference et al, 2017 ; Ji and Lee, 2021 ). Notably, the increased lipid in the serum and liver was reduced with the administration of berberine, which improved intima-media thickening, restored aortic endothelium-dependent vasodilatation, and alleviated atherosclerotic lesions in APOE (−/−) mice fed a western-type diet for 12 weeks ( Tan et al, 2020 ).…”

Section: Effects Of Berberine On Vascular Diseasesmentioning

confidence: 99%

Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases

Peng

et al. 2021

Front. Pharmacol.

View full text Add to dashboard Cite

Traditional Chinese medicine plays a significant role in the treatment of various diseases and has attracted increasing attention for clinical applications. Vascular diseases affecting vasculature in the heart, cerebrovascular disease, atherosclerosis, and diabetic complications have compromised quality of life for affected individuals and increase the burden on health care services. Berberine, a naturally occurring isoquinoline alkaloid form Rhizoma coptidis, is widely used in China as a folk medicine for its antibacterial and anti-inflammatory properties. Promisingly, an increasing number of studies have identified several cellular and molecular targets for berberine, indicating its potential as an alternative therapeutic strategy for vascular diseases, as well as providing novel evidence that supports the therapeutic potential of berberine to combat vascular diseases. The purpose of this review is to comprehensively and systematically describe the evidence for berberine as a therapeutic agent in vascular diseases, including its pharmacological effects, molecular mechanisms, and pharmacokinetics. According to data published so far, berberine shows remarkable anti-inflammatory, antioxidant, antiapoptotic, and antiautophagic activity via the regulation of multiple signaling pathways, including AMP-activated protein kinase (AMPK), nuclear factor κB (NF-κB), mitogen-activated protein kinase silent information regulator 1 (SIRT-1), hypoxia-inducible factor 1α (HIF-1α), vascular endothelial growth factor phosphoinositide 3-kinase (PI3K), protein kinase B (Akt), janus kinase 2 (JAK-2), Ca2+ channels, and endoplasmic reticulum stress. Moreover, we discuss the existing limitations of berberine in the treatment of vascular diseases, and give corresponding measures. In addition, we propose some research perspectives and challenges, and provide a solid evidence base from which further studies can excavate novel effective drugs from Chinese medicine monomers.

show abstract

“…However, due to their high price, they remain underutilized and difficult to prescribe in clinical practice [ 206 ]. Antibodies that neutralize inflammatory cytokines (TNF- α , IL-1β, IL-6, IL-17, and IL-12/23) have shown promising but contradictory results and thus warrant further research [ 207 , 208 ]. Monoclonal antibodies against PCSK9 (alirocumab, evolocumab) were also developed and studied in large clinical programs.…”

Section: Established and Emerging Therapeutical Strategies For Atherosclerosismentioning

confidence: 99%

Inflammation, Oxidative Stress, Senescence in Atherosclerosis: Thioredoxine-1 as an Emerging Therapeutic Target

Hadri

Smith

Duplus

et al. 2021

IJMS

View full text Add to dashboard Cite

Atherosclerosis is a leading cause of cardiovascular diseases (CVD) worldwide and intimately linked to aging. This pathology is characterized by chronic inflammation, oxidative stress, gradual accumulation of low-density lipoproteins (LDL) particles and fibrous elements in focal areas of large and medium arteries. These fibrofatty lesions in the artery wall become progressively unstable and thrombogenic leading to heart attack, stroke or other severe heart ischemic syndromes. Elevated blood levels of LDL are major triggering events for atherosclerosis. A cascade of molecular and cellular events results in the atherosclerotic plaque formation, evolution, and rupture. Moreover, the senescence of multiple cell types present in the vasculature were reported to contribute to atherosclerotic plaque progression and destabilization. Classical therapeutic interventions consist of lipid-lowering drugs, anti-inflammatory and life style dispositions. Moreover, targeting oxidative stress by developing innovative antioxidant agents or boosting antioxidant systems is also a well-established strategy. Accumulation of senescent cells (SC) is also another important feature of atherosclerosis and was detected in various models. Hence, targeting SCs appears as an emerging therapeutic option, since senolytic agents favorably disturb atherosclerotic plaques. In this review, we propose a survey of the impact of inflammation, oxidative stress, and senescence in atherosclerosis; and the emerging therapeutic options, including thioredoxin-based approaches such as anti-oxidant, anti-inflammatory, and anti-atherogenic strategy with promising potential of senomodulation.

show abstract

Antibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases

Cited by 42 publications

References 140 publications

Single antibody detection in a DNA origami nanoantenna

Single antibody detection in a DNA origami nanoantenna

Berberine: A Review of its Pharmacokinetics Properties and Therapeutic Potentials in Diverse Vascular Diseases

Inflammation, Oxidative Stress, Senescence in Atherosclerosis: Thioredoxine-1 as an Emerging Therapeutic Target

Contact Info

Product

Resources

About